Genitourinary Cancer

Panel 03 - (INTERACTIVE) Hypofractionated Radiation Therapy for Localized Prostate Cancer: ASTRO, ASCO, and AUA Guideline Recommendations and Evidentiary Base

Key Questions 3 and 4: Indications and dose-fractionation for ultrahypofractionated RT

Sunday, October 21
5:21 PM - 5:39 PM
Location: Lila Cockrell Theatre

D. Andrew Loblaw, MD, MSc, FRCPC

Odette Cancer Centre

Disclosure:
Employment
Dr. Loblaw Medicine Professional Corp: President: Employee

Compensation
AbbVie: Consultant, Honoraria; Astellas: Advisory Board, Consultant, Honoraria, Travel Expenses; Bayer: Consultant, Honoraria; Bristol-Myers Squibb: Consultant; Ferring: Consultant; Glaxo Smith Kline: Consultant; Janssen: Advisory Board, Honoraria; Janssen Oncology: Consultant, Travel Expenses; Merck: Consultant; Novartis: Consultant; Roche: Consultant; TerSera: Honoraria

Ownership
Sunnybrook Research Institute: Patent/License Fees/Copyright

Leadership
Prostate Cure Foundation: Founder and Chair

Biography:
Dr Andrew Loblaw is a Radiation Oncologist, Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto.

He received a Bachelor of Science in Physics from the University of British Columbia and his Doctor of Medicine from Queen’s University. He completed his specialty training in Radiation Oncology concurrent with a Masters degree in Clinical Epidemiology to graduate from Royal College’s Clinician Investigator Program all at the University of Toronto.

Dr Loblaw’s clinical practice and research interest focus on improving outcomes for men with prostate cancer and the healthcare system. He has a particularly interest in the design and conduct of clinical trials, the generation and dissemination of evidence-based guidelines and in image-guided radiotherapy.

Dr Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Scientist at the Sunnybrook Research Institute. A Fellow of the American Society of Clinical Oncology (FASCO), he was previous Co-Chair of the ASCO’s Genitourinary Advisory Group and remains Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care.

Presentation(s):

Send Email for D. Andrew Loblaw


Assets

Key Questions 3 and 4: Indications and dose-fractionation for ultrahypofractionated RT

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Key Questions 3 and 4: Indications and dose-fractionation for ultrahypofractionated RT